BioTime Stock Jumps 22 Percent in Two Days in Wake of Geron Deal
The stock price of Biotime, Inc., of Alameda, Ca., shot up more than 12 percent today following the announcement of a complex deal that will give it the stem cell assets of Geron Corp., the first firm to launch a clinical trial for an hESC therapy.
Geron stock price Jan. 2-8
Google chart
BioTime stock closed at $3.88, up 43 cents or 12.46 percent. That fol…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.